Europe Cannabis Market 2022-2027

    In Stock

    EUROPE CANNABIS MARKET

     

    INTRODUCTION

    Cannabis would be a tall shrub with such a strong erect stem and is used as a narcotic and is now being approved for medicinal purposes. The research examines the major elements of the legal cannabis industry.

     

    Because cannabis is widely utilised for therapeutic purposes in the region, the cannabis business has expanded and matured tremendously in the United States. Marijuana, as a pharmaceutical drug, continues to be popular in Europe both between medicinal and recreational purposes users.

     

    Cannabis is supplied to patients living with chronic conditions such as Parkinson’s, Alzheimer’s, cancer, and a variety of neurological ailments. CBD oil is becoming more popular due to its fitness and wellness benefits.

     

    Cannabidiol oil is used to treat sadness and anxiety, as well as to protect against diabetes, relieve cancer symptoms, and reduce inflammation. The European marijuana industry is predicted to increase considerably over the coming quarters, owing to the increasing use of cannabidiol (CBD)-based medications to cure diseases.

     

    infographic: Europe Cannabis Market, Europe Cannabis Market Size, Europe Cannabis Market Trends, Europe Cannabis Market Forecast, Europe Cannabis Market Risks, Europe Cannabis Market Report, Europe Cannabis Market Share

     

    Strong regulations requirements governing marijuana marketing and manufacturing in many countries can be difficult for manufacturers and investors to follow. The species also was recognized as hemp; however this name is commonly used in reference primarily to Cannabis types grown for non-drug purposes.

     

    Cannabis has historically been used by the natural fibers, hemp oil as well as lipids, cannabis stalks for vegetable as well as beverage uses, therapeutic applications, and also as a pleasure narcotic. Derived from hemp goods are created from marijuana plants that have been chosen for their high fiber content.

     

    EUROPE CANNABIS MARKET DYNAMICS

    Despite Europe is an enticing market for multinational corporations and investors concerned in recreational marijuana, whose regulatory framework is very scattered. Cannabis legalisation is a relatively recent invention in Europe, despite the fact that every European country has a lengthy history of legalisation support.

     

    But even though the medicinal cannabis industry has grown well entrenched in certain European nations, legislation developers are still struggling to find the best approach to meet consumption.

     

    The availability of healthcare marijuana in Europe aided in the dissemination of cannabis information throughout the continent, showcasing the plant’s therapeutic virtues. Nonetheless, the stigmatized associated with cannabis remains prevalent in European society.

     

    Additionally, in certain European nations, cannabis legalisation is highly controversial among political parties. As a result, legalising cannabis with such an environment may be perilous, as knowledge and marijuana acceptability attempt to provide the groundwork for an evidence-based public conversation on legalizing marijuana.

     

    The instance of legalisation in Malta can help other European countries understand the path that they may pursue. Releaf Malta, a neighbourhood non-profit Organisation, campaigned tirelessly for decades to legalise cannabis upon that country.

     

    From December 2021, this same administration of Malta legalised the cultivation of four to 6 plants in residence, the possession of seven grammes, the establishment of a specialised government body, and the formation of social cannabis clubs. Although sales are still prohibited, this achievement represents a crucial milestone for the cannabis industry in Europe.

     

    In order to research the consequences of cannabis legalization, Switzerland will be the first nation in Europe to begin a cannabis sales pilot programme. The third-most populated city in Switzerland, Basel, is home to 370 participants in the so-called “Weed Care” experimental programme.

     

    The study would look into whether cannabis use in pharmacies affected people’s mental and physical wellbeing. Pharmacies will charge between CHF 8 and CHF 12 per gramme for cannabis-based items, depending on the going rate on the black market. The Swiss firm Pure Production creates goods with various THC concentrations.

     

    A website for selling cannabis products opened in Europe with the goal of promoting “seed-to-shelf” quality and openness. 

     

    A former banker and cannabinoid (CBD) producer launched the Geneva, Switzerland-based CBX Stock Exchange (CBX). A third party, an independent laboratory in Switzerland, has validated the safety and purity of the cannabis products on CBX, an online marketplace for buyers and sellers.

     

    By facilitating trading in cannabis flowers, hemp biomass, distillates and isolates, and tinctures, it links cannabis growers with a variety of businesses, from wellness to beauty.

     

    EUROPE CANNABIS MARKET SEGMENTATION

    The Europe Cannabis Market can be segmented into following categories for further analysis.

    By Application

    • Commercial Application
    • Industrial Application
    • High-Capacity User Application
    • Residential Application

     

    By Usage Classification Type

    • Pain Management
    • Medical Management
    • Neurological Health Management
    • Mental Health Management

     

    By Operational Technology Type

    • Flowers
    • Concentrates
    • Hybrids

     

    By Regional Classification

    • Austria
    • Belgium
    • Bulgaria
    • Croatia
    • Republic of Cyprus
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Greece
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg
    • Malta
    • Netherlands
    • Poland
    • Portugal
    • Romania
    • Slovakia
    • Slovenia
    • Spain
    • Sweden

     

    RECENT TECHNOLOGICAL TRENDS IN EUROPE CANNABIS MARKET

    Cannabis production, distribution, including ownership should indeed be restricted to’ medical and experimental uses’ within international treaties. To dissuade usage, acquisition of the substance for individual consumption ought to be a felony, and most nations make this punishable by jail.

     

    Nonetheless, in recent times, numerous governments have lessened their punishments for marijuana users, and many others have allowed the drug’s distribution, permitting us to see diverse control regimes and their repercussions.

     

    Neither central government throughout Europe favours the liberalization of marijuana for recreational sales, and all nations impose jail penalties for illicit supply. However, various draught legislation have been offered to national legislatures in recent years, as have other proposals in districts or municipalities that have already been denied at the national scale..

     

    It’s indeed, nevertheless, rich in proteins and has powerful plant fibres, making it ideal for usage in the textile, industrial, and consumer goods sectors.

     

    It is a sustainable resource that is used to make plastic polymers, building items, textiles, wood, biofuel, paper, and even automobile components. The first house built with hempcrete; a carbon-neutral construction material composed of hemp.

     

    Aside from that, THC is claimed to contain psychoactive characteristics that provide the high effect of cannabis. As a result, THC-rich strains may be beneficial to persons suffering from physical discomfort, sleeplessness, or sadness.

     

     

    RECENT LAUNCH IN EUROPE CANNABIS MARKET

    Medical Marijuana, Inc., the world’s first publicly traded cannabis company that created cannabis-derived nutraceutical products, brands, and a supply chain, announced today that its subsidiary Kannaway will host its Europe Regional Event in Prague. Its first cannabidiol (CBD) product with 1% THC that can be sold legally throughout the Czech Republic.

     

    Aurora Cannabis has announced the launch of a new patient-focused product line in the United Kingdom. The Berlin-based firm claims to be launching new cannabis extracts for the UK that comply with EU GMP requirements and are created using a revolutionary extraction technique that ensures the terpene profile of its products is maintained at a high level.

     

    Canonic Ltd., a wholly-owned subsidiary of Evogene Ltd. focused on the development of medical-grade cannabis products, announced that it has shipped a first batch of its unique cannabis varieties to Portugal after receiving export approval from the Israeli Ministry of Health and Ministry of Agriculture.

     

    Canonic Ltd is using a Computational Predictive Biology (CPB) platform to produce medical cannabis products. The Company’s in-development products are aimed at increasing the yield of active chemicals, genetic stability, and Cannabis cultivars for specific medical applications.

     

    Dr. Reddy’s Laboratories Ltd. and MediCane Health Inc. announced today that their medicinal cannabis medication is now available in Germany. MediCane will provide Dr. Reddy’s with medicinal cannabis products and logistical and regulatory support from its EU-GMP-certified facilities in Portugal.

     

    Dr. Reddy’s, as the exclusive distributor of the products in Germany, will offer MediCane’s medical cannabis products under its own brand, backed by a specialised field force that can educate healthcare professionals on how to use the products and provide guidance on the health insurance reimbursement process.

     

    RECENT DEVELOPMENT AND INNOVATION IN EUROPE CANNABIS MARKET

    Neuraxpharm, a leading European specialty pharmaceutical company announced the launch of its “Change for Health” campaign, which aims to increase medical cannabis acceptance and provide better information to patients, physicians, and pharmacies.

     

    Neuraxpharm is promoting medical cannabis as a treatment in order to improve the quality of life for hundreds of thousands of patients. Neuraxpharm hopes that through this awareness campaign, healthcare professionals, regulators, patients, and the general public will reconsider their preconceptions about cannabis and embrace it as an effective, individualized treatment option.

     

    Neuraxpharm’s campaign will begin in Germany, the Czech Republic, and Switzerland, and will be expanded to other countries as their legislation evolves. 

     

    Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), and Panaxia, a global pharmaceutical company that develops, manufactures, and markets advanced medical cannabis products of pharmaceutical quality, announced today the signing of two addendums to their collaboration agreement to expand into the Czech and Swiss markets.

     

    Panaxia will market and distribute advanced medical cannabis products, including cannabis extracts for inhalation, as part of the collaboration. This follows previous collaborations between the German and French companies. The collaboration model will be similar to that used in Germany, with Naxiva Panaxol serving as the joint brand.

     

    This agreement strengthens Neuraxpharm and Panaxia’s position as key players in the European medical cannabis -market, and the two companies intend to expand the agreement to other countries.

     

    COMPETITIVE LANDSCAPE

    This past decade seems to have been a key differentiator again for legalized marijuana market, with multiple states legalising marijuana usage for both recreational and therapeutic purposes.

     

    Delivering these items to the general public has necessitated significant scientific advancements. Instead of little treatment, farmers are now producing oils as smoking, pills, edible candies, and other products. It will be intriguing to observe how technology advances impact the manner humans become high as the consumers are entering a new period of marijuana usage.

     

    Tilray Inc. is a leading developer of the Cannabis Production technology as part of medical requirements for integrations in the European market wherein the focus has been on developing large storage farms classified under differential storage classes of operations.

     

    Given the sluggishness that has engulfed the state-wide legalisation movements around the World, which propelled Canadian cannabis values up and up and up a few decades previously, Tilray’s diversification strategy may be the key to long-term success.

     

    And establish one of North America’s most intriguing commercial companies. Having formed a partnership with Aphria, a further Canadian cannabis start-up, to form a new corporation. This resulted in two key alterations to the firm’s destiny.

     

    Aurora Europe is also a leading implementer of medical and person-based cannabis expert in the market. The entity formed an JV wherein the same two firms furthermore made an agreement which grants Aurora entirely separate rights for using EnWave’s Radiant Energy Vacuum (REV) drying innovation throughout all European Union countries but apart from Portugal, as well as a non-exclusive sub-license using the advanced technologies in Canada, and it invested that quantity in Vancouver-based technology firm EnWave.

     

    Aurora will also get the opportunity to solely licence REV technologies in Australia and across South America, with the exception of Peru. Several choices are available if Aurora satisfies the REV program’s minimum spend order criteria.

     

    COMPANIES PROFILED

     

    THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

    1. What is the average cost per Europe Cannabis Market right now and how will it change in the next 5-6 years?
    2. Average cost to set up a Cannabis Market in Europe?
    3. How many Europe Cannabis Market are manufactured per annum globally? Who are the sub-component suppliers in different regions?
    4. What is happening in the overall public, globally?
    5. Cost breakup of a Europe Cannabis Market and key vendor selection criteria
    6. Where is the Europe Cannabis Market  manufactured? What is the average margin per equipment?
    7. Market share of Europe Cannabis Market manufacturers and their upcoming products
    8. The most important planned Europe Cannabis Market in next 2 years
    9. Details on network of major Europe Cannabis Market and pricing plans
    10. Cost advantage for OEMs who manufacture Europe Cannabis Market in-house
    11. 5 key predictions for next 5 years in Europe Cannabis Market
    12. Average B-2-B Europe Cannabis Market price in all segments
    13. Latest trends in Europe Cannabis Market, by every market segment
    14. The market size (both volume and value) of Europe Cannabis Market in 2022-2030 and every year in between?
    15. Global production breakup of Europe Cannabis Market, by suppliers and their OEM relationship

     

    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in theIndustry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2022-2027
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2022-2027
    19 Market Segmentation, Dynamics and Forecast by Application, 2022-2027
    20 Market Segmentation, Dynamics and Forecast by End use, 2022-2027
    21 Product installation rate by OEM, 2022
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2022
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix
     
    0
      0
      Your Cart
      Your cart is emptyReturn to Shop